Medical treatment of intermittent claudication patients: potential protective effects of propionyl-L-carnitine (review)
https://doi.org/10.24884/1682-6655-2023-22-3-14-18
Abstract
Lower extremity peripheral arterial disease (PAD) is a manifestation of systemic atherosclerosis and is recognized by the ankle-brachial index (ABI). PAD patients’ treatment addresses the relief of chronic leg ischemia and prevention of cardiovascular complications of atherosclerosis. The review describes the PAD patients’ management, and highlights the necessity of intermittent claudication effective treatment with regard to its causes. We discuss the medications used for its treatment and analyze the results of reported clinical trials of propionyl-L-carnitine effect on intermittent claudication signs and evaluated its safety. Since the therapeutic doses of propionyl-L-carnitine are safe and have a positive effect on PAD patients with cardiovascular risks, it should be considered to have high clinical relevance in case of intermittent claudication. The propionyl-L-carnitine is considered to be safe in short-term period but its long-term safety evaluation is waiting for further researches.
About the Authors
Yu. V. Lukyanov
Pavlov University
Russian Federation
Russian Federation
Lukyanov Yuriy V. – MD, Professor, Leading Researcher, Cardiovascular Surgery and Emergency Medicine Research Centre
6-8, L’va Tolstogo street, Saint Petersburg, 197022
M. S. Bogomolov
Pavlov University
Russian Federation
Russian Federation
Bogomolov Mikhail S. – Candidate of Sciences (PhD) in Medicine, Associate Professor, Department of Faculty Surgery
6-8, L’va Tolstogo street, Saint Petersburg, 197022
References
1. Tama B, Fabara SP, Zarrate D, Sohail AA. Effectiveness of propionyl-L-carnitine supplementation on exercise performance in intermittent claudication: a systematic review // Cureus. 2021;13(8):e17592. Doi: 10.7759/cureus.17592.
2. O’Connell PR, McCaskie AW, Sayers RD. Bailey and Love’s Short Practice of Surgery, 28th edition // Boca Raton, CRC Press, 2023:1696.
3. Bokeriya LA, Pokrovskiy AV, Akchurin RS i dr. Natsional’nyye rekomendatsii po diagnostike i lecheniyu zabolevaniy arteriy nizhnikh konechnostey. Moscow, 2019:89. (In Russ.)
4. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT) // JAMA. 2002;288(23):2981–2997. Doi: 10.1001/jama.288.23.2981.
5. Momsen AH, Jensen MB, Norager CB, Madsen MR, Vestersgaard-Andersen T, Lindholt JS. Drug therapy for improving walking distance in intermittent claudication: a systematic review and meta-analysis of robust randomised controlled studies // Eur J Vasc Endovasc Surg. 2009;38(4):463– 474. Doi: 10.1016/j.ejvs.2009.06.002.
6. Ankle Brachial Index Collaboration; Fowkes FGR, Murray GD, Butcher I, Heald CL, Lee RJ, Chambless LE, Folsom AR, Hirsch AT, Dramaix M, deBacker G, Wautrecht JC, Kornitzer M, Newman AB, Cushman M, SuttonTyrrell K, Fowkes FG, Lee AJ, Price JF, d’Agostino RB, Murabito JM, Norman PE, Jamrozik K, Curb JD, Masaki KH, Rodríguez BL, Dekker JM, Bouter LM, Heine RJ, Nijpels G, Stehouwer CD, Ferrucci L, McDermott MM, Stoffers HE, Hooi JD, Knottnerus JA, Ogren M, Hedblad B, Witteman JC, Breteler MM, Hunink MG, Hofman A, Criqui MH, Langer RD, Fronek A, Hiatt WR, Hamman R, Resnick HE, Guralnik J, McDermott MM. Ankle Brachial Index Combined With Framingham Risk Score to Predict Cardiovascular Events and Mortality // JAMA. 2008;300(2):197–208. Doi: 10.1001/ jama.300.2.197.
7. Piepoli MF, Hoes AW, Agewall S, Albus Ch, Brotons C, Catapano AL, Cooney M-Th, Corrà U, Cosyns B, Deaton Ch, Graham I, Hall MS, Hobbs FDR, Løchen M-L, Löllgen H, Marques-Vidal P, Perk J, Prescott E, Redon J, Richter DJ, Sattar N, Smulders Y, Tiberi M, van der Worp HB, van Dis I, Verschuren WMM, Binno S; ESC Scientific Document Group. 2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts)Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR) // Eur Heart J. 2016;37(29):2315–2381. Doi: 10.1093/eurheartj/ ehw106.
8. Fokkenrood HJP, Bendermacher BLW, Lauret GJ, Willigendael EM, Prins MH, Teijink JAW. Supervised exercise therapy versus non-supervised exercise therapy for intermittent claudication // Cochrane database Syst Rev. 2013;8(CD005263). Doi: 10.1002/14651858.CD005263.pub3.
9. Polonsky TS, McDermott MM. Lower Extremity Peripheral Artery Disease Without Chronic Limb-Threatening Ischemia. A Review // JAMA. 2021;325(21):2188–2198. Doi: 10.1001/jama.2021.2126.
10. Andreozzi GM. Propionyl L-carnitine: intermittent claudication and peripheral arterial disease // Expert Opin Pharmacother. 2009;10(16):2697–2707. Doi: 10.1517/ 14656560903215871.
11. Сайт ГРЛС. URL: https://grls.pharm-portal.ru/grls?filters %5Binn %5D %5Binns %5D %5B0 %5D %5Bid %5D=be2edc1a4eb9-492b-9e04-b9611c059395 (дата обращения 01.02.23).
12. Hiatt WR, Regensteiner JG, Creager MA, Hirsch AT, Cooke JP, Olin JW, Gorbunov GN, Isner J, Lukjanov YuV, Tsitsiashvili MSh, Zabelskaya TF, Amato A. Propionyl-L-carnitine improves exercise performance and functional status in patients with claudication // Am J Med. 2001;110(8):616–622. Doi: 10.1016/s0002-9343(01)00704-5.
13. Campia U, Gerhard-Herman M, Piazza G, Goldhaber SZ. Peripheral artery disease: past, present, and future // Am J Med. 2019;132(10):1133–41. Doi: 10.1016/j. amjmed.2019.04.043.
14. Fielding R, Riede L, Lugo JP, Bellamine A. L-Carnitine supplementation in recovery after exercise // Nutrients. 2018;10(3):349. Doi: 10.3390/nu10030349.
15. Brevetti G, Diehm C, Lambert D. European multicenter study on Propionyl-l-carnitine in intermittent claudication // J Am Coll Cardiol. 1999;34(5):1618–1624. Doi: 10.1016/ S0735-1097(99)00373-3.
16. Norgren L, Hiatt WR, Dormandy JA, Nehler MR, Harris KA, Fowkes FGR. Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II) // Eur J Vasc Endovasc Surg. 2007;33(Suppl 1):1–75. Doi: 10.1016/j. jvs.2006.12.037.
17. Kamoen V, Vander Stichele R, Campens L, De Bacquer D, Van Bortel L, de Backer TLM. Propionyl-L-carnitine for intermittent claudication // Cochrane Database Syst Rev. 2021;12(CD010117). Doi: 10.1002/14651858.CD010117.pub2.
18. Goldenberg NA, Krantz MJ, Hiatt WR. L-Carnitine plus cilostazol versus cilostazol alone for the treatment of claudication in patients with peripheral artery disease: a multicenter, randomized, double-blind, placebocontrolled trial // Vasc Med. 2012;(17):145–54. Doi: 10.1177/1358863X12442264.
19. Iushchenko AYu. L-carnitine in rehabilitation of patients with cardiovascular diseases // Vestn. fizioterapii i kurortologii. 2020;26(4):80–84. (In Russ.). Doi: 10.37279/2413- 0478-2020-26-4-80-84.
20. Sizova Zh, Shikh E, Makhova A. Use of L-carnitine in general medical practice // Vrach. 2019;(4):20–27. (In Russ.). Doi: 10.26442/00403660.2019. 01.000040.
Review
For citations:
Lukyanov Yu.V., Bogomolov M.S. Medical treatment of intermittent claudication patients: potential protective effects of propionyl-L-carnitine (review). Regional blood circulation and microcirculation. 2023;22(3):14-18. (In Russ.) https://doi.org/10.24884/1682-6655-2023-22-3-14-18
Views:
614
Email this article 
